TNF and psoriasis: In another study, Wu et al. observed that the MACE Hazard Ratio (HR) was 45% lower in patients with psoriasis undergoing TNF inhibitor therapy compared to the conventional Methotrexate treatment group after 12 months, therefore highlighting the beneficial role of anti-TNF use as a therapeutic agent [138].